The TREMFYA® 8-week dosing schedule was researched in clinical trials1-4
TREMFYA® is administered as a 100-mg subcutaneous injection once every 8 weeks, after 2 starter doses at Weeks 0 and 41
TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.
In active psoriatic arthritis, TREMFYA® may be administered alone or in combination with a cDMARD (eg, methotrexate).
*Frequency of maintenance injections for TREMFYA® after the first year.
cDMARD=conventional disease-modifying antirheumatic drug.
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc. 3. Chen Y, Miao X, Hsu C-H, et al. Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patient with psoriatic arthritis. Clin Transl Sci. 2022;15(3):749-760. doi: 10.111/cts.13197 4. Chen Y, Miao X, Hsu C-H, et al. Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis [online supplement, Fig S4]. Clin Transl Sci. 2022;15(3):749-760. doi: 10.111/cts.13197
Injection demonstration videos
Watch these easy-to-follow injection demonstration videos for TREMFYA®.
The injection demonstration videos are not meant to replace the IFU that are supplied with TREMFYA®. Instruct patients to read the IFU before using their TREMFYA® prefilled syringe or One-Press injector and each time they get a refill. Please see the full Instructions for Use (IFU) for TREMFYA®.
One-Press injector demonstration video
Prefilled syringe demonstration video
See how TREMFYA® selectively inhibits IL-23